Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis

Yang, Yaqin; Yang, Xiaoyun; Li, Huaifang; Tong, Xiaowen; Zhu, Xinxian

doi:10.1080/01443615.2022.2151883

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yang et al in its meta-analysis focusing on ovarian cancer demonstrated an insignificant HR of 0.90 (0.75 -1.08) in 95% CI (P = 0.56) for OS but significant PFS outcome (HR, 0.49 (0.36 -0.68) in 95% CI (P < 0.05)). Though they also found that olaparib will significantly increase the side effects' occurrences probability [28]. Another meta-analysis by Liu et al revealed similar outcomes since TNBC patients might benefit well from olaparib administration, with considerable increase in mutated BRCA gene population.…”

Section: Olaparib For Mcrpcmentioning

confidence: 88%

Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

Warli,

Velaro,

Firsty

et al. 2023

World J Oncol

View full text Add to dashboard Cite

Background:The emergence of olaparib, a poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitor to treat metastatic castration-resistant prostate cancer (mCRPC), created a measurable clinical question on whether the agent positively influences the treatment outcomes and acceptable safety factors. The objective was to elaborate on the efficacy and safety of olaparib-added regimens in treating mCRPC patients as compared to the established guideline. Methods:The literature search was performed on several scientific databases, e.g., PubMed, Cochrane, and ScienceDirect, by applying the Boolean Term method. Statistical and risk of bias (RoB) analyses were calculated through RevMan 5.4.1. to investigate our outcomes, i.e., progression-free survival (PFS) and overall survival (OS) with the reported adverse effects (AEs). These outcomes were presented in hazard ratio (HR) and risk ratio (RR).Results: Three trials consisting of 1,325 individuals with comparable baseline characteristics were investigated. The meta-analysis showed that introducing olaparib into the regimens significantly improved the PFS (HR 0.59 (0.48 -0.73); P < 0.05), which disclosed even better outcomes among mutated homologous recombinant repair (HRR) and ataxia-telangiectasia mutated (ATM) gene (HR 0.43 (0.30 -0.62); P < 0.05) in 95% confidence interval (CI). Furthermore, similar outcomes were observed in OS analysis (HR 0.81 (0.67 -0.99); P < 0.05), despite olaparib group disclosed higher AEs rate with insignificant difference in mortality rate. Conclusion:The efficacy and safety of olaparib-added regimens in mCRPC patients need to be explored more extensively in trials because they are beneficial, particularly among HRR-mutated individuals.

show abstract

Section: Olaparib For Mcrpcmentioning

confidence: 88%

Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

Warli,

Velaro,

Firsty

et al. 2023

World J Oncol

View full text Add to dashboard Cite

show abstract

The anthraquinone derivative KA‐4s reduces energy metabolism and enhances the sensitivity of ovarian cancer cells to cisplatin

Zhao,

Li,

et al. 2024

Molecular Carcinogenesis

View full text Add to dashboard Cite

Ovarian cancer is the leading cause of death from female gynecological cancers. Cisplatin (DDP) is a first‐line drug for ovarian cancer treatment. Due to DDP resistance, there is an urgent need for novel therapeutic drugs with improved antitumor activity. AMPK‐mediated metabolic regulatory pathways are related to tumor drug resistance. Our study aimed to determine the relationship between reversing DDP resistance with the anthraquinone derivative KA‐4s and regulating AMPK energy metabolism in ovarian cancer. The results showed that KA‐4s inhibited the proliferation of ovarian cancer cells. The combination of KA‐4s with DDP effectively promoted drug‐resistant ovarian cancer cell apoptosis and inhibited cell migration and invasion. Moreover, KA‐4s decreased the intracellular ATP level and increased the calcium ion level, leading to AMPK phosphorylation. Further studies suggested that the AMPK signaling pathway may be involved in the mechanism through which KA‐4s reduce drug resistance. KA‐4s inhibited mitochondrial respiration and glycolysis; downregulated the glucose metabolism‐related proteins GLUT1 and GLUT4; the lipid metabolism‐related proteins SREBP1 and SCD1; and the drug resistance‐related proteins P‐gp, MRP1, and LRP. The inhibitory effect of KA‐4s on GLUT1 was confirmed by the application of the GLUT1 inhibitor BAY‐876. KA‐4s combined with DDP significantly increased the expression of p‐AMPK and reduced the expression of P‐gp. In a xenograft model of ovarian cancer, treatment with KA‐4s combined with DDP reduced energy metabolism and drug resistance, inducing tumor apoptosis. Consequently, KA‐4s might be evaluated as a new agent for enhancing the chemotherapeutic efficacy of treatment for ovarian cancer.

show abstract

MiRNAs as Regulators of Immune Cells in the Tumor Microenvironment of Ovarian Cancer

Wilczyński,

Nowak

2024

Cells

View full text Add to dashboard Cite

Ovarian cancer is one of the leading causes of cancer deaths among women. There is an ongoing need to develop new biomarkers and targeted therapies to improve patient outcomes. One of the most critical research areas in ovarian cancer is identifying tumor microenvironment (TME) functions. TME consists of tumor-infiltrating immune cells, matrix, endothelial cells, pericytes, fibroblasts, and other stromal cells. Tumor invasion and growth depend on the multifactorial crosstalk between tumor cells and immune cells belonging to the TME. MiRNAs, which belong to non-coding RNAs that post-transcriptionally control the expression of target genes, regulate immune responses within the TME, shaping the landscape of the intrinsic environment of tumor cells. Aberrant expression of miRNAs may lead to the pathological dysfunction of signaling pathways or cancer cell-regulatory factors. Cell-to-cell communication between infiltrating immune cells and the tumor may depend on exosomes containing multiple miRNAs. MiRNAs may exert both immunosuppressive and immunoreactive responses, which may cause cancer cell elimination or survival. In this review, we highlighted recent advances in the field of miRNAs shaping the landscape of immune cells in the TME.

show abstract

Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis

Cited by 3 publications

References 21 publications

Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

The anthraquinone derivative KA‐4s reduces energy metabolism and enhances the sensitivity of ovarian cancer cells to cisplatin

MiRNAs as Regulators of Immune Cells in the Tumor Microenvironment of Ovarian Cancer

Contact Info

Product

Resources

About